Status:
COMPLETED
Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Shenzhen Second People's Hospital
The Seventh Affiliated Hospital of Sun Yat-sen University
Conditions:
Refractory Acute Myeloid Leukemia
Relapsed Acute Erythroid Leukemia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Up Until now, there is not well acepted treatment for relapsed/refractory (rr) acute myeloid luekemia (AML), which has low complete response and poor survival. According to different guildlines, clini...
Eligibility Criteria
Inclusion
- Patients with rrAML Patients with the age of 18-65 years old
Exclusion
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Patients with any conditions not suitable for the trial (investigators' decision)
Key Trial Info
Start Date :
May 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT04424147
Start Date
May 27 2020
End Date
June 30 2022
Last Update
October 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515